Recent Updates
Recently added Catalysts

Small Cell Lung Cancer: 8 biotech companies competing in the clinic

OncologyGold rushData as of 2026-09-04

Competitors8in the clinic
Median market cap$2.0Buniverse median $1.20B
Allocated capital$6.7B$38.1B competing
Phase 3 or filed24 mid, 2 early
Pure plays1this indication only
Capital rank28/299crowding rank 16

Small Cell Lung Cancer is both crowded and richly priced: 8 companies are in the clinic and the median one is worth $2.0B, against a universe median of $1.20B.

Crowded fields usually trade at a discount per company, so a premium in a field this deep says the market is pricing the size of the prize above the cost of the competition.

2 of the 8 are in Phase 3 or filed, and 7 dated catalysts fall in the next 12 months, so this ranking is likely to move.

$6.7B of allocated capital sits in Small Cell Lung Cancer, 28th of 299 indications, and 1 of the 8 companies are pure plays that trade on this indication alone.

Companies developing drugs for Small Cell Lung Cancer 8

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
JAZZJazz PharmaceuticalsLurbinectedinPhase 33$16.1BNo14 30 Sep 2026
ZLABZai LabZL-1310Phase 35$3.1BNo3 31 Dec 2026
SMMTSummit TherapeuticsivonescimabPhase 21$13.7BNo5 14 Nov 2026
DSGNDesign TherapeuticsTopotecan- usualPhase 24$941MNo6 31 Dec 2026
PBYIPuma BiotechnologyAlisertibPhase 22$486MNo3No dated event
FHTXFoghorn TherapeuticsFHD-286Phase 21$289MYes1 31 Dec 2026
IDYAIDEAYA BiosciencesIDE-161Phase 12$3.5BNo3 1 Oct 2026
GNLXGeneluxOlvi-VecPhase 12$113MNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. JAZZ holds 42% of the $38.1B competing in this indication.

Why Small Cell Lung Cancer is a gold rush

Crowded and richly priced: six or more competitors, and the median one is worth more than the median small or mid cap biotech.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Small Cell Lung Cancer has 8 competitors and a median of $2.0B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Ovarian Cancer9 companies · $6.7B · median $1.4BGold rushAcute Myeloid Leukemia15 companies · $7.0B · median $1.2BKnife fightHepatocellular Carcinoma5 companies · $7.3B · median $2.1BConcentrated betColorectal Cancer7 companies · $5.9B · median $723MKnife fightHead and Neck Cancer7 companies · $5.5B · median $1.8BGold rushBiliary Tract Cancer4 companies · $4.6B · median $7.4BConcentrated betWell-differentiated Non-functional Neuroendocrine Tumor1 company · $4.5B · median $9.0BUncontestedBladder Cancer8 companies · $9.1B · median $1.8BGold rush

Small Cell Lung Cancer pipeline questions

Which biotech companies are developing drugs for Small Cell Lung Cancer?

8 US-listed companies in the $100M to $20B market cap band run clinical programmes in Small Cell Lung Cancer. The largest and most advanced are Jazz Pharmaceuticals (JAZZ, Lurbinectedin, Phase 3); Zai Lab (ZLAB, ZL-1310, Phase 3); Summit Therapeutics (SMMT, ivonescimab, Phase 2); Design Therapeutics (DSGN, Topotecan- usual, Phase 2); Puma Biotechnology (PBYI, Alisertib, Phase 2). The full list of 8 is in the table on this page.

How advanced is the Small Cell Lung Cancer pipeline?

Of the 8 clinical-stage programmes in Small Cell Lung Cancer, 2 are in Phase 3 or filed, 4 are in mid-stage development and 2 are in early-stage development.

How much is the typical Small Cell Lung Cancer biotech company worth?

The median company developing a drug for Small Cell Lung Cancer is worth $2.0B, against a median of $1.20B across the whole universe. $6.7B of allocated capital sits in the indication, ranking it 28th of 299.

When is the next Small Cell Lung Cancer catalyst?

The next dated catalyst in Small Cell Lung Cancer is JAZZ on 30 Sep 2026. 7 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map